Seaport Therapeutics, Inc Common Stock

Seaport Therapeutics, Inc Common Stock

Yahoo Finance • 17 days ago

Seaport Therapeutics Reports Wider Net Loss In Q1; Expects Phase 2b BUOY-1 Trial Data In H1,2027

(RTTNews) - Seaport Therapeutics, Inc. (SPTX), reported a wider net loss for its first financial quarter ended March 31, 2026, and provided near term milestone update. Company Profile Seaport Therapeutics is a clinical-stage therapeutics... Full story

Yahoo Finance • 18 days ago

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eli... Full story